Literature DB >> 19953569

An agonistic mAb directed to the TrkC receptor juxtamembrane region defines a trophic hot spot and interactions with p75 coreceptors.

Veronique Guillemard1, Ljubica Ivanisevic, Alba Galan Garcia, Vicki Scholten, Oscar M Lazo, Francisca C Bronfman, H Uri Saragovi.   

Abstract

The D5 domain of TrkC receptors is a docking site for Neurotrophin-3 (NT-3), but other domains may be relevant for function or harmonizing signals with p75(NTR) coreceptors. We report a monoclonal antibody (mAb) 2B7 targeting the juxtamembrane domain of TrkC. mAb 2B7 binds to murine and human TrkC receptors and is a functional agonist that affords activation of TrkC, AKT, and MAPK. These signals result in cell survival but not in cellular differentiation. Monomeric 2B7 Fabs also affords cell survival. Binding of 2B7 mAb and 2B7 Fabs to TrkC are blocked by NT-3 in a dose-dependent manner but not by pro-NT-3. Expression of p75(NTR) coreceptors on the cell surface block the binding and function of mAb 2B7, whereas NT-3 binding and function are enhanced. mAb 2B7 defines a previously unknown neurotrophin receptor functional hot spot; that exclusively generates survival signals; that can be activated by non-dimeric ligands; and potentially unmasks a site for p75-TrkC interactions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19953569     DOI: 10.1002/dneu.20776

Source DB:  PubMed          Journal:  Dev Neurobiol        ISSN: 1932-8451            Impact factor:   3.964


  8 in total

1.  Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor.

Authors:  M Cazorla; J M Arrang; J Prémont
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  In glaucoma the upregulated truncated TrkC.T1 receptor isoform in glia causes increased TNF-alpha production, leading to retinal ganglion cell death.

Authors:  Yujing Bai; ZhiHua Shi; Yehong Zhuo; Jing Liu; Andrey Malakhov; Eunhwa Ko; Kevin Burgess; Henry Schaefer; Pedro F Esteban; Lino Tessarollo; H Uri Saragovi
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-23       Impact factor: 4.799

3.  A monovalent agonist of TrkA tyrosine kinase receptors can be converted into a bivalent antagonist.

Authors:  Fouad Brahimi; Jing Liu; Andrey Malakhov; Shafinaz Chowdhury; Enrico O Purisima; Ljubica Ivanisevic; Antoine Caron; Kevin Burgess; H Uri Saragovi
Journal:  Biochim Biophys Acta       Date:  2010-06-19

4.  Double-targeting using a TrkC ligand conjugated to dipyrrometheneboron difluoride (BODIPY) based photodynamic therapy (PDT) agent.

Authors:  Anyanee Kamkaew; Kevin Burgess
Journal:  J Med Chem       Date:  2013-09-24       Impact factor: 7.446

Review 5.  Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease.

Authors:  Frank M Longo; Stephen M Massa
Journal:  Nat Rev Drug Discov       Date:  2013-07       Impact factor: 84.694

6.  Alternative Splicing of a Receptor Intracellular Domain Yields Different Ectodomain Conformations, Enabling Isoform-Selective Functional Ligands.

Authors:  Fouad Brahimi; Alba Galan; Sean Jmaeff; Pablo F Barcelona; Nicolas De Jay; Kurt Dejgaard; Jason C Young; Claudia L Kleinman; David Y Thomas; H Uri Saragovi
Journal:  iScience       Date:  2020-08-10

7.  The Paradoxical Signals of Two TrkC Receptor Isoforms Supports a Rationale for Novel Therapeutic Strategies in ALS.

Authors:  Fouad Brahimi; Mario Maira; Pablo F Barcelona; Alba Galan; Tahar Aboulkassim; Katrina Teske; Mary-Louise Rogers; Lisa Bertram; Jing Wang; Masoud Yousefi; Robert Rush; Marc Fabian; Neil Cashman; H Uri Saragovi
Journal:  PLoS One       Date:  2016-10-03       Impact factor: 3.240

8.  BDNF, NT-3 and Trk receptor agonist monoclonal antibodies promote neuron survival, neurite extension, and synapse restoration in rat cochlea ex vivo models relevant for hidden hearing loss.

Authors:  Stephanie Szobota; Pranav D Mathur; Sairey Siegel; KristenAnn Black; H Uri Saragovi; Alan C Foster
Journal:  PLoS One       Date:  2019-10-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.